Outlook Therapeutics(R) (NASDAQ:OTLK) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team [Yahoo! Finance]
Outlook Therapeutics, Inc. (OTLK)
Last outlook therapeutics, inc. earnings: 2/14 08:00 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
formulation of bevacizumab to receive European Commission Marketing Authorization for the treatment of wet AMD FRENCHTOWN, NJ / ACCESSWIRE / June 6, 2024 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today released a Virtual Investor "What This Means" segment featuring Outlook Therapeutics, Inc. (Nasdaq:OTLK), a biopharmaceutical company focused on the commercialization and development of ONS-5010/LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma), for the treatment of retina diseases. As part of this "What This Means" segment, Russell Trenary, President and Chief Executive Officer of Outlook Therapeutics, discusses the Company's recently received European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the treatment of wet AMD. The Virtual Investor "What This Means" segment featuring Outlook Therapeutics is now available here . Additional videos from the "What This Means" series are available on demand at www.
Show less
Read more
Impact Snapshot
Event Time:
OTLK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OTLK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OTLK alerts
High impacting Outlook Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
OTLK
News
- Outlook Therapeutics, Inc.'s (NASDAQ:OTLK) largest shareholders are individual investors with 31% ownership, private equity firms own 31% [Yahoo! Finance]Yahoo! Finance
- Outlook Therapeutics(R) (NASDAQ: OTLK) to Participate Virtual Investor Closing Bell Series [Yahoo! Finance]Yahoo! Finance
- Outlook Therapeutics® to Present at the Virtual Investor Pitch Conference [Yahoo! Finance]Yahoo! Finance
- Outlook Therapeutics® to Present at the Virtual Investor Pitch ConferenceGlobeNewswire
- Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMDGlobeNewswire
OTLK
Earnings
- 5/15/24 - Miss
OTLK
Analyst Actions
- 5/17/24 - HC Wainwright
OTLK
Sec Filings
- 6/26/24 - Form DEF
- 6/14/24 - Form PRE
- 5/28/24 - Form 8-K
- OTLK's page on the SEC website